The U.S. clinical oncology next generation sequencing market size was estimated at USD 166.9 million in 2022 and is expected to surpass around USD 687.04 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 15.2% during the forecast period 2023 to 2032.
U.S. Clinical Oncology Next Generation Sequencing Market Report Scope
|Market Size in 2023||USD 192.27 Million|
|Market Size by 2032||USD 687.04 Million|
|Growth Rate From 2023 to 2032||CAGR of 15.2%|
|Forecast Period||2023 to 2032|
|Segments Covered||Technology, workflow, Application, End-use|
|Market Analysis (Terms Used)||Value (US$ Million/Billion) or (Volume/Units)|
|Report Coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Key Companies Profiled||Illumina, Inc.,Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine, Pacific Bioscience, Oxford Nanopore Technologies Ltd.,Qiagen , Macrogen, Inc.|
The key factors attributed to the growth of the market are increasing adoption of NGS, increasing healthcare spending, and the rise in the prevalence of cancer. Moreover, the growth in clinical applications of NGS in precision oncology is expected to propel market demand over the forecast period.
The COVID-19 pandemic has significantly influenced the market. During the COVID-19 pandemic, private participants and government administrations focused on next-generation sequencing technology as a diagnostic instrument in the industry. For instance, in August 2020, the U.S. Food and Drug Administration authorized liquid biopsy NGS companion diagnostic tests to determine mutations in BRCA2 and BRCA1 genes and help treat patients with metastatic castration-resistant prostate cancer. These aspects supported the market demand during the COVID-19 pandemic.
Moreover, the rising number of cancer cases in the country is the major factor propelling the market. The American Cancer Society estimated that over 1.9 million new cancer patients will be diagnosed in the U.S. in 2023. Moreover, as per the U.S. Department of Health & Human Services, in 2020, the country reported 1,603,844 new cancer cases and 602,347 deaths. It further reports that around 20% of deaths in the U.S. causes due to cancer. NGS helps determine novel and rare cancer mutations, identifies familial cancer mutation carriers, and helps find suitable targeted treatments. Therefore, it is anticipated that an upsurge in cancer cases and patients across the globe can drive the demand for clinical oncology in NGS in the country market.
In addition, the increasing healthcare spending in the U.S. is expected to propel the demand for clinical oncology NGS market. According to the Journal published by the National Library Of Medicine in May 2022, cancer care spending in the country surpassed USD 200 billion in 2020. Moreover, every year pocket spending on cancer care is estimated to be around USD 16 billion. This increased spending on cancer care is anticipated to boost the research and development activities related to NGS-based diagnostics and treatments for cancer patients.
Moreover, the increasing adoption of NGS and its clinical applications in precision oncology is anticipated to propel the market growth over the forecast period.Various companies are launching platforms that use NGS for precision oncology and genomic insights. For instance, in June 2021, OmniSeq and LabCorp, the U.S.-based life science company, introduced OmniSeq INSIGHTsm, a next-generation sequencing test designed to advance precision oncology. Moreover, in April 2023, the U.S.-based company Agilent Technologies Inc. introduced Agilent Sure Select Cancer CGP Assay, based on NGS, for advancing precision oncology. Thus, the increasing focus of industry participants on NGS for precision oncology is expected to boost the market demand.
Based on the technology, the U.S. clinical oncology next generation sequencing market is segmented into targeted sequencing & resequencing, whole genome sequencing, and whole exome sequencing. The targeted sequencing & resequencing segment accounted for the largest revenue share of 72.55% in 2022. The increased utility of targeted panels to detect malignant tumors and the advantages associated with this technology, such as reduced cost, time, and amount of data analyzed during the sequencing, can be attributed to the segment's dominance.
Whole-Genome Sequencing (WGS) is expected to grow at the fastest CAGR over the forecast period in the technology segment. The growth of the segment can be attributed to various factors, such as it can be used to get a base pair resolution of an entire genome in a single run and its utility to differentiate and compare tumor tissues from normal tissues. Moreover, whole genome sequencing of cancer patients provides a complete view of the genomic alterations and unique mutations in cancer tissue. These benefits associated with WGS are anticipated to propel the segment growth over the forecast period.
The market is segmented based on workflow into NGS sequencing, NGS pre-sequencing, and NGS data analysis. The NGS sequencing held an enormous share of 55.25% in 2022 in the workflow segment, and it is anticipated to expand at the highest CAGR from 2023 to 2032. The dominance of the segment is due to the rising focus of industry players on NGS technology for oncology treatments, and NGS sequencing is an important step in the complete workflow.
NGS data analysis is anticipated to increase at a significant rate. The rising research and development activities to develop innovative solutions coupled with the increasing prevalence of cancer are expected to boost segment growth over the forecast period. In addition, the technological advancements and increasing efforts by industry participants to introduce novel platforms further propel the market growth. For instance, in March 2023, Illumina Inc., a provider of DNA sequencing technologies, introduced the cloud-based software Connected Insights for the tertiary analysis of clinical NGS. data
Screening accounted for an enormous revenue share of over 80.16% in 2022. The increasing use of NGS in cancer screening worldwide can be attributed to the largest share of the screening segment. Next-generation sequencing provides benefits in sensitivity, accuracy, and speed to notably influence the oncology field. Moreover, it does not require numerous tests to recognize the causative mutation, as NGS can evaluate myriad genes in a single assay. These advantages associated with the NGS are anticipated to support the segment growth over the forecast period.
The companion diagnostics segment is expected to register the highest CAGR of 20.2% over the forecast period. Constant partnerships & collaborations, and product developments, among the major players, are expected to boost the adoption of next-generation sequencing for companion diagnostics. In addition, the regulatory authorities are also supporting product launches in this segment. For instance, in August 2022, the Food and Drug Administration approved a next-generation sequencing-based companion diagnostic test from Thermo Fisher Scientific to help patients suffering from lung cancer.
The laboratories segment held the largest market share, with a revenue share of over 64.14% in 2022. In the U.S., various governing authorities regulate clinical laboratories. The organizations such as the College of American Pathologists (CAP) and the American College of Medical Genetics and Genomics (ACMG) have designed the guidelines for clinical laboratories. Moreover, the U.S. FDA regulates the NGS-based clinical diagnostics test. Such guidelines and recommendations help increase the use of NGS technologies in laboratories.
As an end-use, clinics are expected to witness the highest CAGR over the forecast period due to the increasing prevalence of cancer nationwide and rising research and development activities. Next-generation sequencing has transformed from research to clinical use. Moreover, the increasing number of clinics using NGS for cancer treatment is anticipated to propel the segment growth. For instance, In December 2022, Mayo Clinic Laboratories introduced MayoComplete oncology next-generation sequencing (NGS) panels for comprehensive care.
Key Companies & Market Share Insights
Numerous participants are operating in the market. Firms in the industry are undertaking numerous strategies, such as launching novel products, partnerships & collaborations, to maintain their market presence. For instance, in June 2023, PreCheck Health Services Inc., a U.S.-based company, introduced a comprehensive cancer panel utilizing Next Generation Sequencing technology. In addition, in June 2023, Invivoscribe, the U.S.-based provider of oncology testing products and services, collaborated with Complete Genomics, a provider of DNA sequencing solutions, to design biomarker tests for oncology and cancer research. In this partnership, Complete Genomics is offering NGS platforms. Some of the key players in the U.S. clinical oncology next generation sequencing market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Clinical Oncology Next Generation Sequencing market.